Background: The clinical utility of plasma tumor mutational burden (pTMB) requires further
validation. Herein, the pTMB and genetic alterations were investigated as predictive …

Osteosarcoma (OS) is a rare but aggressive malignancy. Despite previous reports,
molecular characterization of this disease is not well understood, and little is known …

The identification of targets that are expressed on the cell membrane is a main goal in
cancer research. The Lymphocyte Antigen 6 Family Member G6D (LY6G6D) gene codes for …

Background Tumor mutation burden (TMB) is a promising biomarker positively associated
with the benefit of immunotherapy and that might predict the outcome of chemotherapy. We …

Tumor mutational burden (TMB) and T‐cell receptor (TCR) might predict the response to
immunotherapy in patients with non–small cell lung cancer (NSCLC). However, the …

Importance Total neoadjuvant therapy (TNT) is the standard treatment for locally advanced
rectal cancer, especially for patients with high-risk factors. However, the efficacy of TNT …

Background Lung adenocarcinoma (LUAD), the most common histotype of lung cancer, may
have variable prognosis due to molecular variations. The research strived to establish a …

BAP-1 (BRCA1-associated protein 1) inactivated melanocytic lesions are a group of familial
or sporadic lesions with unique histology and molecular features. They are of great clinical …

Abstract Background Only 15–20% of recurrent and/or metastatic squamous cell carcinoma
of the head and neck (R/M SCCHN) patients derive long-term benefit from nivolumab or …

Objective: Tumor suppressor genes (TSGs) play critical roles in the cell cycle checkpoints
and in modulating genomic stability. Here, we aimed to develop a TSG-based prognostic …